


## About Vidac

Vidac Pharma is a private clinical-stage oncology and onco-dermatology biopharmaceutical company developing first-in-class drugs. Its unique immuno-metabolic platform technology targets the metabolic checkpoint hexokinase 2 (HK2), affecting both cancer and immune cells. Vidac's drugs modulate HK2 to trigger cancer cell death, reduce immunosuppression, and stimulate anti-tumor immune response. Vidac is developing its drugs to treat cancers that depend on glycolysis and express high levels of HK2. Lead drug VDA-1102 – a first-in-class HK2 modulator – successfully completed a clinical Phase 2a proof-of-concept trial in actinic keratosis (AK), an early form of skin cancer, demonstrating efficacy, safety, and tolerability. The Phase 2b study in AK is ongoing, with data expected in 2H 2018. Phase I/II trials in solid tumors and hematological malignancies with VDA-1102 injection are expected in 2019.

### Immuno-metabolism platform technology: *Modulating the metabolic checkpoint HK2*

Metabolic re-programming to aerobic glycolysis, known as the Warburg effect, allows cancer cells and some types of activated immune cells (e.g., macrophages and T-cells) an efficient conversion of glucose to biomass and energy required for rapid cell growth and proliferation. Hexokinase 2 (HK2), which catalyzes the first step of glucose metabolism, is a metabolic checkpoint for this process, and is selectively over-expressed in cancer and activated immune cells. The association of HK2 with the mitochondria (via the VDAC channel) results in prevention of cell death and supports proliferation. Vidac platform technology focuses on novel small-molecule drugs that modulate the HK2 metabolic checkpoint, detaching it from the mitochondria. Preclinical data show that Vidac's metabolic checkpoint modulators destroy cancer cells and improve immune responses against tumors.

Vidac's HK2 modulators activate multiple anti-tumor mechanisms



### Oncology and onco-dermatology pipeline

Vidac is developing its drugs to treat cancers that depend on glycolysis and express high levels of HK2. These include many types of solid tumors and hematological malignancies including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), castration resistant prostate cancer (CRPC), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). In addition, various types of skin cancers express high levels of HK2, including cutaneous squamous cell carcinoma (SCC), cutaneous T-cell lymphoma (CTCL), and melanoma. An ointment formulation of VDA-1102 is currently being advanced (Phase 2) as a first-in-class non-irritating topical drug for actinic keratosis (AK), an early form of cutaneous SCC. Initiation of Phase I/II trials in solid tumors and hematological malignancies with VDA-1102 formulated as an injection is expected in 2019.



First-in-Class Portfolio in Dermatology and Oncology

Program	Indication	Discovery	Preclinical POC	Phase 1	Phase 2	Phase 3
Dermatology		SELECTIVE TARGETING OF CANCER CELLS				
VDA-1102 ointment	Actinic Keratosis				2018	
VDA-1102 ointment	CTCL					
Oncology		IMMUNO-METABOLICS				
VDA-1102 injection	Solid Tumors					
VDA-1275	Solid Tumors					

**VDA-1102 in actinic keratosis (AK)**

Actinic keratosis (AK) is an early form of skin cancer which if left untreated may progress to invasive cutaneous squamous cell carcinoma (cSCC). AK is very prevalent, affecting 50 million people in the US alone, leading to an annual rate of 9 million visits to dermatologists. The current global AK market exceeds \$6.6B, with sales of topical AK drugs exceeding \$2B. As approved treatment options are unsightly, very irritating and painful, patients often avoid initial and follow-up treatment making AK an unmet medical need.

Topical VDA-1102 ointment is poised to be a first-in-class non-irritating topical drug for AK. VDA-1102 ointment successfully completed a clinical Phase 2a proof-of-concept trial in AK demonstrating efficacy, safety, and exceptional tolerability. Vidac’s Phase 2b study in AK is ongoing, with data expected in 2H 2018. VDA-1102 is highly-differentiated from all the approved topical AK treatments and is poised to win over the topical portion of the AK market (2 million patients a year in US) with projected revenue in excess of \$500M a year from the US alone. Comparable markets exist in Europe and Australia.

**Leadership**

Oren M. Becker, PhD, *President and Chief Executive Officer*

24 years of industry experience. Formerly at Dynamix (founder, CEO), Epix (CSO), Predix (founder, CSO), Immunity Pharma (co-founder, director). Former professor at Tel Aviv University and Harvard.

Vered Behar, PhD, MBA, *Chief Science Officer*

17 years of industry experience. Formerly at Dynamix (VP); Quantomix (CSO), and Pfizer. PhD from Harvard University.

Chaim M. Brickman, MD, *Chief Medical Officer*

41 years of clinical experience. MD from Albert Einstein College of Medicine, NY. Board-certified in the US and Israel. Fellowship at the National Institutes of Health. Former professor at Wayne State University Medical Ctr, Michigan. More recently at Inotek Pharma and Teva.

Paul Salama, PhD, *Vice President & CMC*

17 years of industry experience. Formerly at Chiasma (VP CMC), Inotek Pharma, Delmar Chemicals. Former professor at U. of Moncton, Canada. PhD from University of Montreal.

**Contact information**

Oren Becker: obecker@vidacpharma.com P +972-2-5952090

Vidac Pharma, 10 Hartom Street, Har Hotzvim, PO Box 45342 Jerusalem, Israel 9777510

This Corporate Fact Sheet contains forward-looking statements that involve substantial risks and uncertainties. Other than statements of historical facts, statements regarding Vidac's strategy, future operations, outlook, milestones, the success of Vidac's product development, potential advantages of Vidac's product candidates, plans and objectives of management are forward-looking statements. Vidac may not actually achieve these plans or objectives and investors are cautioned not to place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make. Such factors include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of our product candidates, our ability to enhance the development of our product candidates, regulatory risks, and our reliance on third party researchers and other collaborators. Vidac is providing this information as of the date noted above and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.